Neubase Therapeutics inc (NBSE) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access NBSE Annual Balance Sheets →
Looking at balance sheet data from Neubase Therapeutics inc through Sep 30 2022 provides insight into Sep 30 2023's solvency and capital structure over time.
Quarterly Report, GAAP in USD millions
ITEM
(Sep 30 2023)
(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Assets
Cash & cash equivalent12.57
Security Deposit0.13
Cash & Short-term Investments12.00
Other Current Assets0.56
Total loans net0.09
Total Current Assets13.35
Equipment/Property/Plant Net0.08
Other Assets, Noncurrent5.19
Assets Held For Sale Not Part Of Disposal Group Current0.43
Other Assets Total5.19
Operating Lease Right Of Use Asset5.06
Total Assets18.62
Liabilities
Accounts Payable, Current AC0.26
Accrued Liabilities, Current AC0.46
Derivative Liability, Current DE3.43
Other Liabilities, Current0.50
Total Current Liabilities4.65
Total Long-term Debt0.00
Other liabilities, Noncurrent4.83
OperatingLeaseLiabilityNoncurrent4.83
Operating Lease Liability Current0.50
Total Liabilities9.48
Stockholders' Equity
Common Stock Value0.00
Additional Paid In Capital Common Stock125.61
Retained Earnings / Accumulated Deficit-116.47
Other Equity0.00
Common Stockholder's Equity9.14
Total Stockholder's Equity9.14
Liabilities & Stockholder's Equity18.62
4 historic quarters locked

Sign in to unlock the full Neubase Therapeutics inc balance sheet history.

About Neubase Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001558370-23-018577

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.